HilleVax

HLVX

Market cap $105M

Overview Fund Activity

2.09 USD

0.00

0%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

2.09

0.00

0%

1 day

0%

5 days

0%

1 month

1.46%

3 months

8.85%

6 months

18.08%

Year to date

0.48%

1 year

20.81%

5 years

-89.05%

10 years

-89.05%

About: HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Employees: 14

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

34% more capital invested

Capital invested by funds: $61.5M [Q1] → $82.5M (+$21M) [Q2]

25% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]

1.35% less ownership

Funds ownership: 84.08% [Q1] → 82.73% (-1.35%) [Q2]

10% less funds holding

Funds holding: 81 [Q1] → 73 (-8) [Q2]

36% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 22

40% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 30

See Fund Rankings

Financial journalist opinion

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of HilleVax, Inc. (NasdaqGS: HLVX) to XOMA Royalty Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HilleVax will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under certain conditions. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of HilleVax will receive $1.95 per share in cash plus contingent value right.

Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)

NEW YORK , Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating HilleVax, Inc. (NASDAQ: HLVX) related to its sale to XOMA Royalty Corporation.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)

HilleVax Reports Second Quarter 2025 Financial Results

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second Quarter Financial Results As of June 30, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and $171.4 million, respectively.

HilleVax Reports Second Quarter 2025 Financial Results

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of HilleVax, Inc. (NasdaqGS: HLVX) to XOMA Royalty Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HilleVax will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under cert.

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by HilleVax, Inc. (NASDAQ: HLVX) and its board of directors concerning the proposed acquisition of the company by XOMA Royalty Corporation (NASDAQ: XOMA). Stockholders will receive $1.95 in cash and one contingent value right for each share of HilleVax stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

Shareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Aug. 4, 2025 /PRNewswire/ -- The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Shareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public Shareholders

HLVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of HilleVax, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of HilleVax, Inc. (NASDAQ: HLVX) to XOMA Royalty Corporation is fair to HilleVax shareholders. Under the terms of the proposed transaction, HilleVax stockholders will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under certain conditions. Halper Sadeh encourages HilleVax shareholders to click here t.

HLVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of HilleVax, Inc. Is Fair to Shareholders

Kosmos Energy Posts Downbeat Q2 Results, Joins HilleVax And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 200 points on Monday.

Kosmos Energy Posts Downbeat Q2 Results, Joins HilleVax And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

BOSTON, Mass., and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive merger agreement (the “Merger Agreement”), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.

HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

See News Rankings

Charts implemented using Lightweight Charts™